Re: Rheumatoid Arthritis Therapy That Re-educates Body's ImmuneResponse

[Guest guest]

a, this is big. Wow, Dr. Albani!

I'll tell you where to go!

Mayo Clinic in Rochester

http://www.mayoclinic.org/rochester

s Hopkins Medicine

http://www.hopkinsmedicine.org

[ ] Rheumatoid Arthritis Therapy That Re-educates

Body's ImmuneResponse

Source: University of California, San Diego Released: Wed

21-Apr-2004, 06:30 ET

Rheumatoid Arthritis Therapy That Re-educates Body's Immune Response

NEW THERAPY FOR RHEUMATOID ARTHRITIS

Description

A promising new therapy for rheumatoid arthritis (RA) developed by

researchers at the University of California, San Diego School of

Medicine

re-educates the body's immune system to prevent an attack against

healthy

joint tissue.

Newswise < A promising new therapy for rheumatoid arthritis (RA)

developed

by researchers at the University of California, San Diego (UCSD) School

of

Medicine re-educates the body's immune system to prevent an attack

against

healthy joint tissue.

In patients with RA, the immune system that is supposed to protect the

body,

instead attacks it for unknown reasons. In a Phase I/IIa clinical trial

recently described in Proceedings of the National Academy of Sciences*,

the

UCSD researchers report that a peptide called dnaJP1, taken orally for

six

months by a group of patients with early RA, caused no side effects and

actually changed the action of the immune system's T cells, preventing

them

from attacking the body's own tissues

The new therapy is currently in Phase II clinical trials with 160 RA

patients at UCSD, s Hopkins University, the Mayo Clinic, and

Virginia

Mason Medical Center in Seattle. It is expected to be completed by the

end

of 2004, with enrollment still open for interested study participants.

RA is a chronic, painful disease that causes joint inflammation and

destruction, progressive disability and premature death. Affecting an

estimated 2.1 million Americans, RA causes substantial economic burden,

with

50 percent of patients unable to work within 10 years of onset, and

lifetime

costs of the disease rivaling those of coronary artery disease or

stroke.**

RA is incurable, with most therapy focused on symptom relief.

Unfortunately,

current therapies can have serious side effects and work by suppressing

the

immune system, which increases the risk of infection.

While the precise cause of the disease is unknown, researchers believe

that

RA is influenced by an abnormal reaction to environmental factors such

as

infection, which initiate the autoimmune response in genetically

susceptible

individuals.

The immune-modulation therapy developed by Salvatore Albani, M.D.,

Ph.D.,

UCSD professor of medicine and pediatrics, takes advantage of both the

genetic and environmental components of RA. In studies over the past 12

years, he has focused on the immune system's T cells, which trigger

inflammation to kill and clear foreign pathogens from the body. Albani

reasoned that if the immune system of RA patients could be altered, T

cells

might be less likely to cause chronic inflammation.

His research involved several components of the immune response,

beginning

with a sequence of amino acids (segments that comprise proteins)

expressed

on the surface of cells during an immune response. Called a human

leukocyte

antigen (HLA), this sequence is designed to recognize self- from

non-self

cells. In a normal immune response, HLA acts as a " natural dimmer " to

prevent over-stimulation of the inflammatory response. In RA patients,

however, the dimmer is broken and excessive inflammation ravages tissue

and

joints. Interestingly, researchers have determined that 70 percent of RA

patients, and not normal individuals, share a specific sequence of five

amino acids within their HLA.

Albani's current findings were further supported by previous studies he

conducted with Dennis Carson, M.D., UCSD professor of medicine and

director

of the Sam and Rose Stein Institute on Aging at UCSD, that showed

immune-system T cells in RA patients become confused by the body's

natural

HLA sequence on cell surfaces, thinking it is a foreign invader. In an

attempt to protect the body, the T cells attack the HLA sequence by

inducing

inflammation.

To prevent T cells from attacking the body's own HLA sequence, Albani

sought

to develop a vaccine therapy that could re-educate the diseased immune

system in RA patients to prevent rampant inflammation. He focused on a

naturally occurring protein called dnaJ that is used by T cells to help

initiate the inflammation process. A section of the dnaJ protein, called

dnaJP1, contains the same sequence of five amino acids as those within

the

HLA of RA patients. Bacterial, non-human forms of the dnaJP1 peptide

also

contained the same sequence of RA-susceptible HLA amino acids, and were

found by the UCSD team to be targets of pro-inflammatory T cell

responses in

RA patients.

" Therefore, we believed that if we could administer the bacterial dnaJP1

as

a vaccine to patients with early RA, it would affect the autoimmune

inflammation, " Albani said. " A key to the treatment was oral

administration

of dnaJP1. "

The researchers determined that an injection of dnaJP1 caused a typical

RA-inflammatory immune response, because T cells recognize the peptide

as a

foreign invader. When the peptide was ingested by patients, however, the

special properties of the digestive system's mucosal cells recognized

dnaJP1

as a " self-peptide, " rather than foreign, and tolerated it. It's the

same

mechanism the digestive system uses with food, which is also a foreign

invader to the body. The mucosal system is designed to tolerate the

food, or

medications, that enter the body in this manner.

" In essence, we re-educated the immune system T cells in RA patients to

be

tolerant of the dnaJP1 amino acid sequence that would usually trigger

inflammation, " Albani said. " In turn, the immune system became tolerant

of

the HLA sequence, thus avoiding a T cell attack against the body's own

tissue. "

He added that " the findings with dnaJP1 offer a strategy and the tools

to

develop a new therapy for RA that focuses on immune modulation rather

than

immune suppression. "

Immune modulation may be particularly helpful in delaying, or possibly

abolishing the need for RA patients to take currently available drugs

called

disease modifying antiarthritic drugs (DMARDs), which provide

significant

improvements in RA but have potentially serious side effects such as

skin

rash; mouth sores; stomach, eye and kidney problems; and low blood

counts.

The University of California has licensed to Androclus Therapeutics, a

biotechnology company located in Milan, Italy and San Diego, California,

exclusive rights to further develop a new therapy based on these

discoveries

In addition to Albani, authors of the paper in Proceedings of the

National

Academy of Sciences were first author Berent J. Prakken, M.D., Ph.D.,

UCSD

Departments of Medicine and Pediatrics and IACOPO Institute for

Translational Medicine; and Rodrigo Samodal, M.D., Tho D. Le, M.S.,

Francesca Giannoni, M.S., Gisella Puga Yung, M.S., Scavulli, M.D.,

Diane Amox, R.N., Roord, M.D., Isme de Kleer, M.D., Dustan Bonnin,

M.S., Berry, Ph.D., and Margherita Massa, Ph.D., UCSD

Departments of

Medicine and Pediatrics and IACOPO Institute for Translational Medicine;

and

Paola Lanza, M.S. and rio Billetta, M.S., Androclus Therapeutics,

Milan,

Italy and San Diego, California. Prakken, Roord, and de Kleer are also

affiliated with the Department of Pediatric Immunology, University

Medical

Center Utrecht, The Netherlands. Massa is also affiliated with Istituo

de

Ricovero e Cura a Carattere Scientifico, Pavia, Italy. Albani is

affiliated

with Androclus Therapeutics.

The Phase I study was funded by the National Institutes of Health (NIH),

the

Royal Netherlands Academy of Arts and Sciences, and the Dutch

Organization

for Scientific Research. The current Phase II trial is funded by the

NIH.

* Proceedings of the National Academy of Sciences, March 23, 2004, Vol.

101,

No. 12, pages 4228-4233.

** Journal of the American Medical Association, Vol. 285, No. 5, Feb. 7,

2001, pages 648-650.

[Guest guest]

VERY big . This is potential treatment for ALL autoimmune diseases.

It¹s interesting that they

are still having open enrollment to be in the clinical trial. Considering

there are no side effects, it

sounds very interesting.

a

> a, this is big. Wow, Dr. Albani!

>

>

>

>

> I'll tell you where to go!

>

> Mayo Clinic in Rochester

> http://www.mayoclinic.org/rochester

>

> s Hopkins Medicine

> http://www.hopkinsmedicine.org

>

>

> [ ] Rheumatoid Arthritis Therapy That Re-educates

> Body's ImmuneResponse

>

>

> Source: University of California, San Diego Released: Wed

> 21-Apr-2004, 06:30 ET

> Rheumatoid Arthritis Therapy That Re-educates Body's Immune Response

>

> NEW THERAPY FOR RHEUMATOID ARTHRITIS

>

>

>

> Description

> A promising new therapy for rheumatoid arthritis (RA) developed by

> researchers at the University of California, San Diego School of

> Medicine

> re-educates the body's immune system to prevent an attack against

> healthy

> joint tissue.

>

> Newswise < A promising new therapy for rheumatoid arthritis (RA)

> developed

> by researchers at the University of California, San Diego (UCSD) School

> of

> Medicine re-educates the body's immune system to prevent an attack

> against

> healthy joint tissue.

>

> In patients with RA, the immune system that is supposed to protect the

> body,

> instead attacks it for unknown reasons. In a Phase I/IIa clinical trial

> recently described in Proceedings of the National Academy of Sciences*,

> the

> UCSD researchers report that a peptide called dnaJP1, taken orally for

> six

> months by a group of patients with early RA, caused no side effects and

> actually changed the action of the immune system's T cells, preventing

> them

> from attacking the body's own tissues

>

> The new therapy is currently in Phase II clinical trials with 160 RA

> patients at UCSD, s Hopkins University, the Mayo Clinic, and

> Virginia

> Mason Medical Center in Seattle. It is expected to be completed by the

> end

> of 2004, with enrollment still open for interested study participants.

>

> RA is a chronic, painful disease that causes joint inflammation and

> destruction, progressive disability and premature death. Affecting an

> estimated 2.1 million Americans, RA causes substantial economic burden,

> with

> 50 percent of patients unable to work within 10 years of onset, and

> lifetime

> costs of the disease rivaling those of coronary artery disease or

> stroke.**

> RA is incurable, with most therapy focused on symptom relief.

> Unfortunately,

> current therapies can have serious side effects and work by suppressing

> the

> immune system, which increases the risk of infection.

>

> While the precise cause of the disease is unknown, researchers believe

> that

> RA is influenced by an abnormal reaction to environmental factors such

> as

> infection, which initiate the autoimmune response in genetically

> susceptible

> individuals.

>

> The immune-modulation therapy developed by Salvatore Albani, M.D.,

> Ph.D.,

> UCSD professor of medicine and pediatrics, takes advantage of both the

> genetic and environmental components of RA. In studies over the past 12

> years, he has focused on the immune system's T cells, which trigger

> inflammation to kill and clear foreign pathogens from the body. Albani

> reasoned that if the immune system of RA patients could be altered, T

> cells

> might be less likely to cause chronic inflammation.

>

> His research involved several components of the immune response,

> beginning

> with a sequence of amino acids (segments that comprise proteins)

> expressed

> on the surface of cells during an immune response. Called a human

> leukocyte

> antigen (HLA), this sequence is designed to recognize self- from

> non-self

> cells. In a normal immune response, HLA acts as a " natural dimmer " to

> prevent over-stimulation of the inflammatory response. In RA patients,

> however, the dimmer is broken and excessive inflammation ravages tissue

> and

> joints. Interestingly, researchers have determined that 70 percent of RA

> patients, and not normal individuals, share a specific sequence of five

> amino acids within their HLA.

>

> Albani's current findings were further supported by previous studies he

> conducted with Dennis Carson, M.D., UCSD professor of medicine and

> director

> of the Sam and Rose Stein Institute on Aging at UCSD, that showed

> immune-system T cells in RA patients become confused by the body's

> natural

> HLA sequence on cell surfaces, thinking it is a foreign invader. In an

> attempt to protect the body, the T cells attack the HLA sequence by

> inducing

> inflammation.

>

> To prevent T cells from attacking the body's own HLA sequence, Albani

> sought

> to develop a vaccine therapy that could re-educate the diseased immune

> system in RA patients to prevent rampant inflammation. He focused on a

> naturally occurring protein called dnaJ that is used by T cells to help

> initiate the inflammation process. A section of the dnaJ protein, called

> dnaJP1, contains the same sequence of five amino acids as those within

> the

> HLA of RA patients. Bacterial, non-human forms of the dnaJP1 peptide

> also

> contained the same sequence of RA-susceptible HLA amino acids, and were

> found by the UCSD team to be targets of pro-inflammatory T cell

> responses in

> RA patients.

>

> " Therefore, we believed that if we could administer the bacterial dnaJP1

> as

> a vaccine to patients with early RA, it would affect the autoimmune

> inflammation, " Albani said. " A key to the treatment was oral

> administration

> of dnaJP1. "

>

> The researchers determined that an injection of dnaJP1 caused a typical

> RA-inflammatory immune response, because T cells recognize the peptide

> as a

> foreign invader. When the peptide was ingested by patients, however, the

> special properties of the digestive system's mucosal cells recognized

> dnaJP1

> as a " self-peptide, " rather than foreign, and tolerated it. It's the

> same

> mechanism the digestive system uses with food, which is also a foreign

> invader to the body. The mucosal system is designed to tolerate the

> food, or

> medications, that enter the body in this manner.

>

> " In essence, we re-educated the immune system T cells in RA patients to

> be

> tolerant of the dnaJP1 amino acid sequence that would usually trigger

> inflammation, " Albani said. " In turn, the immune system became tolerant

> of

> the HLA sequence, thus avoiding a T cell attack against the body's own

> tissue. "

>

> He added that " the findings with dnaJP1 offer a strategy and the tools

> to

> develop a new therapy for RA that focuses on immune modulation rather

> than

> immune suppression. "

>

> Immune modulation may be particularly helpful in delaying, or possibly

> abolishing the need for RA patients to take currently available drugs

> called

> disease modifying antiarthritic drugs (DMARDs), which provide

> significant

> improvements in RA but have potentially serious side effects such as

> skin

> rash; mouth sores; stomach, eye and kidney problems; and low blood

> counts.

>

> The University of California has licensed to Androclus Therapeutics, a

> biotechnology company located in Milan, Italy and San Diego, California,

> exclusive rights to further develop a new therapy based on these

> discoveries

>

> In addition to Albani, authors of the paper in Proceedings of the

> National

> Academy of Sciences were first author Berent J. Prakken, M.D., Ph.D.,

> UCSD

> Departments of Medicine and Pediatrics and IACOPO Institute for

> Translational Medicine; and Rodrigo Samodal, M.D., Tho D. Le, M.S.,

> Francesca Giannoni, M.S., Gisella Puga Yung, M.S., Scavulli, M.D.,

> Diane Amox, R.N., Roord, M.D., Isme de Kleer, M.D., Dustan Bonnin,

> M.S., Berry, Ph.D., and Margherita Massa, Ph.D., UCSD

> Departments of

> Medicine and Pediatrics and IACOPO Institute for Translational Medicine;

> and

> Paola Lanza, M.S. and rio Billetta, M.S., Androclus Therapeutics,

> Milan,

> Italy and San Diego, California. Prakken, Roord, and de Kleer are also

> affiliated with the Department of Pediatric Immunology, University

> Medical

> Center Utrecht, The Netherlands. Massa is also affiliated with Istituo

> de

> Ricovero e Cura a Carattere Scientifico, Pavia, Italy. Albani is

> affiliated

> with Androclus Therapeutics.

>

> The Phase I study was funded by the National Institutes of Health (NIH),

> the

> Royal Netherlands Academy of Arts and Sciences, and the Dutch

> Organization

> for Scientific Research. The current Phase II trial is funded by the

> NIH.

>

> * Proceedings of the National Academy of Sciences, March 23, 2004, Vol.

> 101,

> No. 12, pages 4228-4233.

> ** Journal of the American Medical Association, Vol. 285, No. 5, Feb. 7,

> 2001, pages 648-650.

>

>

>

>

[Guest guest]

I live within driving distance of the Mayo clinic and might be

interested in participatin in this research. However, when I checked

the Mayo website, I had difficulty locating information this clinical

trial.

Do you think you could help me find an appropriate contact? Thanks a

million!

Sierra

> VERY big . This is potential treatment for ALL autoimmune

diseases.

> It¹s interesting that they

> are still having open enrollment to be in the clinical trial.

Considering

> there are no side effects, it

> sounds very interesting.

> a

>

>

> > a, this is big. Wow, Dr. Albani!

> >

> >

> >

> >

> > I'll tell you where to go!

> >

> > Mayo Clinic in Rochester

> > http://www.mayoclinic.org/rochester

> >

> > s Hopkins Medicine

> > http://www.hopkinsmedicine.org

> >

> >

> > [ ] Rheumatoid Arthritis Therapy That Re-

educates

> > Body's ImmuneResponse

> >

> >

> > Source: University of California, San Diego Released:

Wed

> > 21-Apr-2004, 06:30 ET

> > Rheumatoid Arthritis Therapy That Re-educates Body's Immune

Response

> >

> > NEW THERAPY FOR RHEUMATOID ARTHRITIS

> >

> >

> >

> > Description

> > A promising new therapy for rheumatoid arthritis (RA) developed by

> > researchers at the University of California, San Diego School of

> > Medicine

> > re-educates the body's immune system to prevent an attack against

> > healthy

> > joint tissue.

> >

> > Newswise < A promising new therapy for rheumatoid arthritis (RA)

> > developed

> > by researchers at the University of California, San Diego (UCSD)

School

> > of

> > Medicine re-educates the body's immune system to prevent an attack

> > against

> > healthy joint tissue.

> >

> > In patients with RA, the immune system that is supposed to

protect the

> > body,

> > instead attacks it for unknown reasons. In a Phase I/IIa clinical

trial

> > recently described in Proceedings of the National Academy of

Sciences*,

> > the

> > UCSD researchers report that a peptide called dnaJP1, taken

orally for

> > six

> > months by a group of patients with early RA, caused no side

effects and

> > actually changed the action of the immune system's T cells,

preventing

> > them

> > from attacking the body's own tissues

> >

> > The new therapy is currently in Phase II clinical trials with 160

RA

> > patients at UCSD, s Hopkins University, the Mayo Clinic, and

> > Virginia

> > Mason Medical Center in Seattle. It is expected to be completed

by the

> > end

> > of 2004, with enrollment still open for interested study

participants.

> >

> > RA is a chronic, painful disease that causes joint inflammation

and

> > destruction, progressive disability and premature death.

Affecting an

> > estimated 2.1 million Americans, RA causes substantial economic

burden,

> > with

> > 50 percent of patients unable to work within 10 years of onset,

and

> > lifetime

> > costs of the disease rivaling those of coronary artery disease or

> > stroke.**

> > RA is incurable, with most therapy focused on symptom relief.

> > Unfortunately,

> > current therapies can have serious side effects and work by

suppressing

> > the

> > immune system, which increases the risk of infection.

> >

> > While the precise cause of the disease is unknown, researchers

believe

> > that

> > RA is influenced by an abnormal reaction to environmental factors

such

> > as

> > infection, which initiate the autoimmune response in genetically

> > susceptible

> > individuals.

> >

> > The immune-modulation therapy developed by Salvatore Albani, M.D.,

> > Ph.D.,

> > UCSD professor of medicine and pediatrics, takes advantage of

both the

> > genetic and environmental components of RA. In studies over the

past 12

> > years, he has focused on the immune system's T cells, which

trigger

> > inflammation to kill and clear foreign pathogens from the body.

Albani

> > reasoned that if the immune system of RA patients could be

altered, T

> > cells

> > might be less likely to cause chronic inflammation.

> >

> > His research involved several components of the immune response,

> > beginning

> > with a sequence of amino acids (segments that comprise proteins)

> > expressed

> > on the surface of cells during an immune response. Called a human

> > leukocyte

> > antigen (HLA), this sequence is designed to recognize self- from

> > non-self

> > cells. In a normal immune response, HLA acts as a " natural

dimmer " to

> > prevent over-stimulation of the inflammatory response. In RA

patients,

> > however, the dimmer is broken and excessive inflammation ravages

tissue

> > and

> > joints. Interestingly, researchers have determined that 70

percent of RA

> > patients, and not normal individuals, share a specific sequence

of five

> > amino acids within their HLA.

> >

> > Albani's current findings were further supported by previous

studies he

> > conducted with Dennis Carson, M.D., UCSD professor of medicine and

> > director

> > of the Sam and Rose Stein Institute on Aging at UCSD, that showed

> > immune-system T cells in RA patients become confused by the body's

> > natural

> > HLA sequence on cell surfaces, thinking it is a foreign invader.

In an

> > attempt to protect the body, the T cells attack the HLA sequence

by

> > inducing

> > inflammation.

> >

> > To prevent T cells from attacking the body's own HLA sequence,

Albani

> > sought

> > to develop a vaccine therapy that could re-educate the diseased

immune

> > system in RA patients to prevent rampant inflammation. He focused

on a

> > naturally occurring protein called dnaJ that is used by T cells

to help

> > initiate the inflammation process. A section of the dnaJ protein,

called

> > dnaJP1, contains the same sequence of five amino acids as those

within

> > the

> > HLA of RA patients. Bacterial, non-human forms of the dnaJP1

peptide

> > also

> > contained the same sequence of RA-susceptible HLA amino acids,

and were

> > found by the UCSD team to be targets of pro-inflammatory T cell

> > responses in

> > RA patients.

> >

> > " Therefore, we believed that if we could administer the bacterial

dnaJP1

> > as

> > a vaccine to patients with early RA, it would affect the

autoimmune

> > inflammation, " Albani said. " A key to the treatment was oral

> > administration

> > of dnaJP1. "

> >

> > The researchers determined that an injection of dnaJP1 caused a

typical

> > RA-inflammatory immune response, because T cells recognize the

peptide

> > as a

> > foreign invader. When the peptide was ingested by patients,

however, the

> > special properties of the digestive system's mucosal cells

recognized

> > dnaJP1

> > as a " self-peptide, " rather than foreign, and tolerated it. It's

the

> > same

> > mechanism the digestive system uses with food, which is also a

foreign

> > invader to the body. The mucosal system is designed to tolerate

the

> > food, or

> > medications, that enter the body in this manner.

> >

> > " In essence, we re-educated the immune system T cells in RA

patients to

> > be

> > tolerant of the dnaJP1 amino acid sequence that would usually

trigger

> > inflammation, " Albani said. " In turn, the immune system became

tolerant

> > of

> > the HLA sequence, thus avoiding a T cell attack against the

body's own

> > tissue. "

> >

> > He added that " the findings with dnaJP1 offer a strategy and the

tools

> > to

> > develop a new therapy for RA that focuses on immune modulation

rather

> > than

> > immune suppression. "

> >

> > Immune modulation may be particularly helpful in delaying, or

possibly

> > abolishing the need for RA patients to take currently available

drugs

> > called

> > disease modifying antiarthritic drugs (DMARDs), which provide

> > significant

> > improvements in RA but have potentially serious side effects such

as

> > skin

> > rash; mouth sores; stomach, eye and kidney problems; and low blood

> > counts.

> >

> > The University of California has licensed to Androclus

Therapeutics, a

> > biotechnology company located in Milan, Italy and San Diego,

California,

> > exclusive rights to further develop a new therapy based on these

> > discoveries

> >

> > In addition to Albani, authors of the paper in Proceedings of the

> > National

> > Academy of Sciences were first author Berent J. Prakken, M.D.,

Ph.D.,

> > UCSD

> > Departments of Medicine and Pediatrics and IACOPO Institute for

> > Translational Medicine; and Rodrigo Samodal, M.D., Tho D. Le,

M.S.,

> > Francesca Giannoni, M.S., Gisella Puga Yung, M.S., Scavulli,

M.D.,

> > Diane Amox, R.N., Roord, M.D., Isme de Kleer, M.D., Dustan

Bonnin,

> > M.S., Berry, Ph.D., and Margherita Massa, Ph.D., UCSD

> > Departments of

> > Medicine and Pediatrics and IACOPO Institute for Translational

Medicine;

> > and

> > Paola Lanza, M.S. and rio Billetta, M.S., Androclus

Therapeutics,

> > Milan,

> > Italy and San Diego, California. Prakken, Roord, and de Kleer are

also

> > affiliated with the Department of Pediatric Immunology, University

> > Medical

> > Center Utrecht, The Netherlands. Massa is also affiliated with

Istituo

> > de

> > Ricovero e Cura a Carattere Scientifico, Pavia, Italy. Albani is

> > affiliated

> > with Androclus Therapeutics.

> >

> > The Phase I study was funded by the National Institutes of Health

(NIH),

> > the

> > Royal Netherlands Academy of Arts and Sciences, and the Dutch

> > Organization

> > for Scientific Research. The current Phase II trial is funded by

the

> > NIH.

> >

> > * Proceedings of the National Academy of Sciences, March 23,

2004, Vol.

> > 101,

> > No. 12, pages 4228-4233.

> > ** Journal of the American Medical Association, Vol. 285, No. 5,

Feb. 7,

> > 2001, pages 648-650.

> >

> >

> >

> >

[Guest guest]

Sierra,

posted the link earlier today. This link has the locations as well as

contact information.

http://www.clinicaltrials.gov/ct/show/NCT00000435?order=6

a

> I live within driving distance of the Mayo clinic and might be

> interested in participatin in this research. However, when I checked

> the Mayo website, I had difficulty locating information this clinical

> trial.

> Do you think you could help me find an appropriate contact? Thanks a

> million!

>

> Sierra

>

[Guest guest]

Thanks--I've already sent them an e-mail. I'm glad you and told

me where to go! :-) I'll keep you posted.

Sierra

> Sierra,

> posted the link earlier today. This link has the locations

as well as

> contact information.

>

> http://www.clinicaltrials.gov/ct/show/NCT00000435?order=6

>

> a

>

>

> > I live within driving distance of the Mayo clinic and might be

> > interested in participatin in this research. However, when I

checked

> > the Mayo website, I had difficulty locating information this

clinical

> > trial.

> > Do you think you could help me find an appropriate contact?

Thanks a

> > million!

> >

> > Sierra

> >

>

>

>

>

[Guest guest]

Please keep us updated! This is very interesting.

a

> Thanks--I've already sent them an e-mail. I'm glad you and told

> me where to go! :-) I'll keep you posted.

>

> Sierra

>

>

>> > Sierra,

>> > posted the link earlier today. This link has the locations

> as well as

>> > contact information.

>> >

>> > http://www.clinicaltrials.gov/ct/show/NCT00000435?order=6

>> >